Rheumatology—The Art of the Science:  Informed Decisions, Improved Outcomes

CME Workshop Series

Jointly sponsored by North American Center for Continuing Medical Education, LLC, and the University of Cincinnati

CORE™ is supported by educational grants from Genentech, Inc and Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, and Abbott Laboratories.

Program Chairs

Marc D. Cohen, MD
Professor of Medicine
National Jewish Medical and Research Center
Denver, Colorado

Eric M. Ruderman, MD
Associate Professor of Medicine
Division of Rheumatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

CORE – 3 Years of Esteemed Faculty
Check NACCME.com/CORE to see who will be presenting in your area.

CORE presents continuing medical education designed to fit YOUR schedule!

Live Workshops Locations, Dates & Times:*

*Dates/Times and Venues are subject to change. We encourage you to please visit http://www.naccme.com/CORE/  frequently to confirm all information with the updated schedule.

Target Audience

This activity is designed for rheumatologists and other healthcare professionals who manage the treatment of patients with rheumatoid arthritis and other rheumatic diseases.

Workshop Agenda

(2 presentations for 1 workshop)

1. RA Therapy in 2010: What Are Today's Best Practices?
2. Managing Inflammatory Arthritis Beyond 2010: A Look Into the Future

After completing this activity, participants should be able to:

• Explain how clinical measurement tools have been used to achieve tight RA control and summarize how these tools can be used in clinical practice to optimize patient care
• Describe advances in imaging techniques for the diagnosis of RA and evaluation of RA disease progression
• Outline genetic associations, laboratory markers, and clinical manifestations which should be considered when initiating early, aggressive RA therapy
• Evaluate the current ACR/EULAR diagnostic and treatment criteria and their impact on the management of RA patients
• Interpret new safety and efficacy data, including those presented at ACR/ARHP, on combination therapy, triple DMARD therapy, and biologic switching
• Apply clinical trial and comprehensive registry data and available guidelines regarding current and emerging pharmacologic agents into clinical practice to achieve low disease activity or remission in patients with RA
• Employ best practices for treating RA in patients with comorbid conditions
• Describe new treatment targets and novel approaches for RA patients who have failed on conventional therapies, including mechanisms of action and safety considerations
• Compare and contrast diagnostic practices and treatment approaches for patients with SpA versus RA

PLUS: Patient Scenarios – RA and SpA Case Resolutions

Activity Overview

To be eligible for documentation of credit, participants must attend the full activity and complete an evaluation form online at NACCME.com.  All individuals who participate in the workshop and submit the evaluation form online at NACCME.com will immediately receive documentation of credit.

There is no fee associated with this activity.

For questions regarding this educational activity, please contact Angela Scarnici at 609-371-1137.

CME Accreditation

The University of Cincinnati is accredited by the American Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Cincinnati designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Planning Committee

The planning committee comprises Marc D. Cohen, MD, Eric M. Ruderman, MD; Key Weigand, University of Cincinnati; Rosemary Hodgson, Emilie McCardell, Greg Paladino, Randy Robbin, John Savage, William Kormos, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity.  All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest.  If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.               

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Faculty disclosure information will be included in the activity materials.

Ms. Weigand, Ms. Hodgson, Ms. McCardell, Mr. Paladino, Mr. Robbin, Mr. Savage, and Mr. Kormos have disclosed no relevant financial relationships with any commercial interest.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Off-label/Unapproved uses of drugs and/or devices will be included in the activity materials.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2010 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support

CORE™ is supported by educational grants from Genentech, Inc and Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, and Abbott Laboratories.